Dyleva Yu A, Gruzdeva O V, Belik E V, Akbasheva O E, Uchasova E G, Borodkina D A, Sinitsky M Yu, Sotnikov A V, Kozyrin K A, Karetnikova V N, Barbarash O L
Research Institute for Complex Issues of Cardiovascular Disease, Kemerovo, Russia.
Research Institute for Complex Issues of Cardiovascular Disease, Kemerovo, Russia; Kemerovo State Medical University, Kemerovo, Russia.
Biomed Khim. 2019 Apr;65(3):239-244. doi: 10.18097/PBMC20196503239.
The purpose of the study was to investigate the features of expression and adiponectin content in the adipocyte culture of subcutaneous, epicardial, and perivascular adipose tissue and the effect of various doses of rosuvastatin on these processes. 29 patients with coronary artery disease were examined. Adipocytes were isolated from the samples of SAT, EAT and PVAT which were taken during coronary artery bypass surgery, followed by cultivation in the presence of rosuvastatin and evaluation of gene expression and adiponectin concentration. Adipocytes SAT, EAT and PVAT differed in the level of adiponectin secretion and expression of its gene. On day 1 of cultivation the expression of the adiponectin gene in the EAT was 2.3 times lower than in the PVAT. On day 2 of cultivation the expression of the adiponectin gene was reduced both in the EAT and the PVAT as compared to the SAT. When rosuvastatin was added at a concentration of 1 mmol/L, adiponectin gene expression in PVAT was higher than when rosuvastatin was added at a concentration of 5 mmol/L, in the adipocyte culture of SAT effect was opposite. Thus, the adipocytes of EZhT and, to a greater extent, PAS, can be a therapeutic target for statins in the case of the pathological activation of adipose tissue.
本研究的目的是调查皮下、心外膜和血管周围脂肪组织的脂肪细胞培养中脂联素的表达特征和含量，以及不同剂量瑞舒伐他汀对这些过程的影响。对29例冠心病患者进行了检查。从冠状动脉搭桥手术期间采集的皮下脂肪组织（SAT）、心外膜脂肪组织（EAT）和血管周围脂肪组织（PVAT）样本中分离脂肪细胞，然后在瑞舒伐他汀存在的情况下进行培养，并评估基因表达和脂联素浓度。SAT、EAT和PVAT的脂肪细胞在脂联素分泌水平及其基因表达方面存在差异。在培养第1天，EAT中脂联素基因的表达比PVAT低2.3倍。在培养第2天，与SAT相比，EAT和PVAT中脂联素基因的表达均降低。当以1 mmol/L的浓度添加瑞舒伐他汀时，PVAT中脂联素基因的表达高于以5 mmol/L的浓度添加瑞舒伐他汀时，而在SAT的脂肪细胞培养中效果相反。因此，在脂肪组织病理激活的情况下，EAT的脂肪细胞以及在更大程度上PAS的脂肪细胞可能是他汀类药物的治疗靶点。
